---
canonical_name: DSIP
alternate_names: Delta Sleep-Inducing Peptide, Delta-Sleep-Inducing Peptide, WAGGDASGE
canonical_topic: DSIP for Health & Longevity
short_topic_lc: dsip
creation_date: 2026-0701-0005
creator_ai_fullname: Opus 4.8
---

# DSIP for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/01/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** Delta Sleep-Inducing Peptide, Delta-Sleep-Inducing Peptide, WAGGDASGE


## Motivation

<!-- This motivation section was written last, after all other sections were completed, so that it reflects the full scope of the topic. -->

Delta sleep-inducing peptide is a tiny natural molecule — a chain of nine amino acid building blocks — first pulled from the blood of sleeping rabbits in the 1970s. Researchers gave it its name because, in early animal work, it appeared to trigger the slow brain waves seen in the deepest stage of sleep. It is of interest to people focused on long-term health because deep sleep is when the body does much of its repair, and a compound that could deepen or restore that sleep is appealing to anyone trying to protect their long-term resilience.

The peptide became a research curiosity for decades. A handful of small human studies in chronic poor sleepers reported better sleep and daytime alertness, while other work found no reliable effect, leaving its true activity unsettled. More recently it has resurfaced in the wider community that experiments with peptides for recovery and sleep, sold only as an unapproved research chemical.

This review examines what is known about delta sleep-inducing peptide: how it is thought to work, what the human and animal evidence shows for sleep and other claimed effects, its safety profile, and the state of its evidence base.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-level overviews and expert commentary that introduce DSIP and its claimed role in sleep and recovery.

<!-- Real-time web searches were performed for "DSIP" and "delta sleep-inducing peptide" combined with each priority expert (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension) via web search and direct site checks. Huberman Lab is the only priority expert with content naming DSIP: it is mentioned briefly within a broader peptides discussion (the "Biohacks For A Better Human Experience" guest episode), not in a dedicated overview. Rhonda Patrick, Peter Attia, Chris Kresser, and Life Extension have no content addressing DSIP by name. The items below are the most substantive non-excluded overviews and narrative/primary sources available; the Huberman mention is too brief and embedded to serve as a high-level standalone overview. -->

* [Delta sleep-inducing peptide (DSIP): a still unresolved riddle](https://pubmed.ncbi.nlm.nih.gov/16539679/) - Kovalzon & Strekalova, 2006

  A concise narrative review that critically assesses whether DSIP is genuinely a sleep factor, concluding the evidence is weak and proposing that a related, still-unidentified peptide may explain its reported activity.

* [Delta sleep-inducing peptide](https://pubmed.ncbi.nlm.nih.gov/11437870/) - Pollard & Pomfrett, 2001

  A short editorial overview in an anaesthesia journal that summarizes DSIP's claimed sleep, anticonvulsant, and stress-protective properties and flags how little is firmly established about its mechanism.

* [Delta-sleep-inducing peptide (DSIP): an update](https://pubmed.ncbi.nlm.nih.gov/3550726/) - Graf & Kastin, 1986

  A detailed narrative review by two of the field's most prolific investigators, cataloguing the early sleep, pain, and withdrawal work and the natural distribution of DSIP-like material in the body.

* [Acute and delayed effects of DSIP on human sleep behavior](https://pubmed.ncbi.nlm.nih.gov/6895513/) - Schneider-Helmert et al., 1981

  The first controlled human study of synthetic DSIP, in six healthy volunteers, reporting increased sleep without classic sedation and serving as the foundation for later therapeutic claims.

* [Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity?](https://pubmed.ncbi.nlm.nih.gov/19849801/) - Gimble et al., 2009

  A narrative review connecting DSIP-immunoreactive material to circadian regulation of fat tissue, offering rare context for any metabolic or longevity-oriented interest in the molecule.

*Note: Among the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine), only Huberman Lab names DSIP, and only as a brief aside within a broader peptides discussion rather than a dedicated overview; the other four have not addressed DSIP by name in any article, podcast, or video as of this review. Because no priority expert offers a substantive high-level DSIP overview, the list above draws on the strongest available narrative reviews and the foundational human study instead.*


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "delta sleep-inducing peptide"; a dedicated article exists at /page/Delta-sleep-inducing_peptide. -->

* [Delta-sleep-inducing peptide](https://grokipedia.com/page/Delta-sleep-inducing_peptide)

  The Grokipedia entry summarizes DSIP's discovery, nine-amino-acid sequence, distribution in the body, and the contradictory state of the sleep evidence, providing a compact reference overview.


## Examine

<!-- examine.com was searched directly using the browser tool for "delta sleep inducing peptide"; no dedicated article exists — results returned only unrelated delta-9-THC and peptide entries. -->

No Examine article exists for DSIP. Examine.com focuses on dietary supplements and does not cover DSIP, which is an injectable research peptide rather than a consumer supplement.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "delta sleep inducing peptide"; no product test or article exists. ConsumerLab tests commercially marketed supplements and does not cover injectable research peptides. -->

No ConsumerLab article exists for DSIP. ConsumerLab tests retail dietary supplements and does not evaluate injectable research peptides such as DSIP.


## Systematic Reviews

<!-- A real-time PubMed search was performed for "delta sleep-inducing peptide" AND ("systematic review" OR "meta-analysis"). No systematic review or meta-analysis specific to DSIP was identified; the available literature consists of narrative reviews, small clinical studies, and animal work. -->

No systematic reviews or meta-analyses for DSIP were found on PubMed as of 07/01/2026.


## Mechanism of Action

DSIP is a small, water- and fat-attracting peptide of nine amino acids (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with a molecular weight of about 850 daltons. Despite its name, how it influences sleep — if it does — has never been firmly established, and no specific DSIP receptor or gene has been identified.

The leading proposed mechanisms include:

* **Slow-wave (delta) sleep promotion:** In early rabbit experiments, infusing DSIP into the brain increased the slow brain-wave activity that defines deep sleep. The effect has been inconsistent across species and laboratories.

* **Neuroendocrine modulation:** DSIP-like material is found in the hypothalamus and pituitary (the brain's hormone-control centers) and may influence the release of stress and growth-related hormones, though human data on cortisol (the main stress hormone) show no consistent effect.

* **NMDA-receptor and adrenergic signaling:** Some animal studies suggest DSIP acts through NMDA receptors (a glutamate-sensing channel involved in brain excitability) and through α₁-adrenergic receptors (which respond to the alertness chemical noradrenaline), which may underlie its reported anticonvulsant and stress-protective effects.

* **Antioxidant and stress-protective actions:** A large body of Russian animal research reports that DSIP and its analogues reduce oxidative damage (harm from reactive molecules) and protect tissues during physical and emotional stress.

Competing mechanistic views exist. The 2006 review by Kovalzon and Strekalova argues that DSIP itself is largely inactive and that a related, still-unidentified peptide may account for the "DSIP-like" effects reported in the literature — directly challenging the idea that DSIP is a true sleep factor.

As a pharmacological compound, DSIP has a very short plasma half-life of roughly 15 minutes, broken down rapidly by enzymes called aminopeptidases. It is not selective for a single known receptor, distributes into the brain, gut, pancreas, and pituitary, and is cleared by enzymatic breakdown rather than by liver CYP (cytochrome P450) enzymes, since it is a peptide rather than a small-molecule drug.


## Historical Context & Evolution

* **Original discovery and intended use:** DSIP was first isolated in 1974 by the Schoenenberger-Monnier research group in Basel, Switzerland, from the blood of rabbits placed in an induced sleep state. It was named for its apparent ability to induce slow-wave ("delta") sleep, and the original interest was in understanding the body's own sleep-regulating signals.

* **Why it was considered for health optimization:** Once a synthetic version was made, researchers tested it for insomnia, chronic pain, and drug and alcohol withdrawal through the late 1970s and 1980s, hoping for a natural, non-sedating sleep aid. Small studies in chronic poor sleepers reported improved sleep and daytime alertness without the grogginess of sleeping pills.

* **The actual findings:** Controlled human studies were small and mixed. The 1981 study in six healthy volunteers reported increased sleep without classic sedation; a 1987 placebo-controlled study in 14 chronic insomniacs reported improved night sleep and daytime performance. Other investigations found no reliable effect, and attempts to link DSIP to a specific gene, precursor, or receptor repeatedly failed.

* **Evolution of scientific opinion:** Enthusiasm faded through the 1990s as the sleep findings could not be consistently reproduced and the molecule's basic biology stayed obscure. The 2006 "unresolved riddle" review reframed DSIP as a poorly documented hypothesis rather than an established sleep factor. Rather than being formally disproven, DSIP was largely set aside; what changed was the recognition that the early claims rested on small, hard-to-replicate studies, while newer animal work continued to report stress-protective and antioxidant effects that remain unconfirmed in humans.

* **Recent resurgence:** Since the 2010s, DSIP has reappeared in the wider peptide-experimentation community, sold as an unapproved research chemical for sleep and recovery despite the unchanged thinness of the human evidence.


## Expected Benefits

A dedicated search of PubMed, narrative reviews, and clinical and peptide-focused sources was performed to compile the complete benefit profile before writing this section.

### High 🟩 🟩 🟩

*No benefits of DSIP qualify for a High evidence grade. No large, replicated, high-quality human trials support any benefit.*

### Medium 🟩 🟩

*No benefits of DSIP qualify for a Medium evidence grade.*

### Low 🟩

#### Improved Sleep in Chronic Insomnia

The most-cited human claim is that DSIP improves sleep quality and daytime functioning in people with chronic insomnia. A small placebo-controlled, double-blind study in 14 middle-aged chronic insomniacs reported improved night sleep with the first and repeated doses, with daytime alertness and performance reaching near-normal levels; an earlier double-blind study in healthy volunteers reported increased sleep without classic sedation. The evidence basis is a handful of small early trials with no large modern replication, several of which come from the same investigator, so confidence is low.

**Magnitude:** In the 1987 trial of 14 chronic insomniacs, night-sleep efficiency and daytime rest reportedly rose to the range of normal controls; precise effect sizes were not robustly quantified.

#### Reduced Symptoms During Withdrawal States ⚠️ Conflicted

DSIP was investigated in the 1980s as an aid during alcohol and opioid withdrawal, with some early open reports describing reduced withdrawal severity. The proposed mechanism is stress-axis and neuroendocrine modulation. The evidence is conflicting: findings come from small, mostly uncontrolled or older studies, and no modern controlled trial has confirmed a withdrawal benefit, leaving the effect uncertain.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Stress Resilience and Antistress Protection

A large body of animal research, predominantly from Russian laboratories, reports that DSIP and its analogues protect organs and tissues against physical and emotional stress. The basis is mechanistic and preclinical only, with no controlled human data, so this remains speculative for people.

#### Antioxidant and Longevity-Related Effects

Animal studies in aging rats report that DSIP raises the activity of the body's own antioxidant enzymes, reduces oxidative damage to proteins, and improves the function of cellular energy machinery during aging. This is the principal basis for any "longevity" interest, but the evidence is entirely preclinical and mechanistic, with no human outcome data.

#### Anticonvulsant Activity

In rodent seizure models, DSIP and an analogue reduced seizure activity, and it has been discussed alongside other endogenous anticonvulsants. The basis is animal experiments only, with no human epilepsy trials.

#### Neuroprotection and Recovery After Stroke

In a rat model of stroke, intranasal DSIP accelerated recovery of motor function, though it did not significantly shrink the area of brain damage. This is a single preclinical signal with no human confirmation.


## Benefit-Modifying Factors

* **Genetic polymorphisms:** No specific genetic variants are known to modify DSIP's effects, reflecting the absence of an identified receptor or metabolic pathway. No pharmacogenetic guidance exists.

* **Baseline sleep and biomarker status:** The early human studies suggested the clearest signal in people with genuinely disturbed sleep (chronic insomniacs) rather than normal sleepers, implying baseline sleep impairment may be a precondition for any noticeable benefit.

* **Sex-based differences:** No reliable sex-based differences in benefit have been characterized; the small human studies were not powered to detect them.

* **Pre-existing health conditions:** Conditions that themselves disrupt sleep (chronic pain, mood disorders, withdrawal states) were the original target populations, so the presence of such conditions may influence whether any sleep benefit is perceived.

* **Age:** Animal antioxidant and anti-aging findings come specifically from aged animals, suggesting age-related decline may be relevant in theory; however, no human age-stratified data exist, including for older adults in the target range.


## Potential Risks & Side Effects

A dedicated search of peptide reference sources, narrative reviews, and the clinical literature was performed to compile the complete risk and side-effect profile before writing this section. A central caveat is that the formal human safety database for DSIP is very small and dated.

### High 🟥 🟥 🟥

*No risks of DSIP qualify for a High evidence grade, owing to the absence of large modern safety studies.*

### Medium 🟥 🟥

*No risks of DSIP qualify for a Medium evidence grade.*

### Low 🟥

#### Unverified Product Quality and Contamination

Because DSIP is sold only as an unapproved research chemical, the most concrete real-world risk is not from the peptide itself but from the product. Research-grade material varies widely in purity, and vials may carry bacterial toxins (endotoxins) or incorrect contents. The mechanism of harm is injection of impure or contaminated material; the evidence basis is the documented variability of the gray-market peptide supply rather than DSIP-specific clinical reports.

**Magnitude:** Not quantified in available studies; commercial purity is commonly reported anywhere from below 95% to above 98% depending on supplier.

#### Mild Injection-Related and Sedative Effects

Reported effects of DSIP use include drowsiness, mild headache, brief nausea after injection, light-headedness on standing, and injection-site irritation. The mechanism is the peptide's intended sedative-adjacent action plus the physical act of subcutaneous injection. The evidence basis is early study tolerability notes and contemporary user reports rather than systematic safety data, so severity appears low but is poorly characterized.

**Magnitude:** Not quantified in available studies; early controlled studies reported the compound was well tolerated with no measured physiological or biochemical side effects.

### Speculative 🟨

#### Unknown Long-Term and Hormonal Effects

DSIP-like material co-localizes with stress, thyroid, and growth-related hormones in the pituitary, raising the theoretical possibility of neuroendocrine disruption with repeated use. No long-term human safety data exist, so any chronic or hormonal risk is speculative and based on the molecule's distribution rather than observed harm.

#### Altered Dream Activity

Users frequently report more vivid or intense dreams on nights DSIP is used. This is based on anecdotal reports only, with no controlled confirmation, and its clinical significance is unknown.

#### Theoretical Vasomotor and Blood-Pressure Effects

Some early animal work noted blood-pressure changes after DSIP administration. Whether this translates to any meaningful cardiovascular effect in humans is unknown and rests on isolated preclinical observations.


## Risk-Modifying Factors

* **Genetic polymorphisms:** No genetic variants are known to modify DSIP-related risk, consistent with its undefined receptor and metabolism.

* **Baseline biomarker levels:** No baseline laboratory values have been shown to predict adverse responses; the safety database is too small to establish any.

* **Sex-based differences:** No sex-based differences in risk have been characterized in the available human data.

* **Pre-existing health conditions:** People with low blood pressure or a tendency to faint may theoretically be more sensitive to any light-headedness, and those with hormone-sensitive conditions warrant caution given the peptide's pituitary distribution; both are inferred rather than demonstrated.

* **Age:** No age-specific risk data exist for DSIP, including for older adults in the target range; the absence of modern safety studies means age-related vulnerability cannot be ruled out.


## Key Interactions & Contraindications

* **Prescription drug interactions:** No formal interaction studies exist. Combining DSIP with prescription sedatives, sleep medications, or benzodiazepines (anti-anxiety and sleep drugs such as diazepam, lorazepam) could theoretically add to sedation. **Severity: caution; clinical consequence: excessive drowsiness.** Mitigating action: avoid combining sedating agents.

* **Over-the-counter medication interactions:** Over-the-counter sleep aids and antihistamines (e.g., diphenhydramine, doxylamine) may compound any sedative effect. **Severity: caution; clinical consequence: additive drowsiness.** Mitigating action: avoid stacking sleep aids.

* **Supplement interactions:** No documented supplement interactions exist for DSIP specifically. **Severity: caution; clinical consequence: unknown.**

* **Additive (same-direction) supplements:** Sleep-promoting supplements such as melatonin, magnesium, valerian, and L-Theanine (a calming amino acid found in tea) would be expected to act in the same direction as DSIP and could deepen sedation if combined. **Severity: caution; clinical consequence: additive sedation/grogginess.** Mitigating action: separate or avoid concurrent use.

* **Other intervention interactions:** Alcohol and other central nervous system depressants would be expected to potentiate sedation and are best avoided.

* **Populations who should avoid this intervention:** Pregnant individuals (any trimester) or those breastfeeding; people with hormone-sensitive conditions (e.g., active estrogen- or androgen-receptor-positive cancers, untreated thyroid disease) given the peptide's pituitary co-localization; people with symptomatic low blood pressure (resting systolic <90 mmHg) or a history of fainting, given the reported light-headedness; anyone unwilling or unable to verify product quality; and people seeking an approved, regulated therapy, since DSIP is not approved for any human use.


## Risk Mitigation Strategies

* **Verify product purity and sterility:** Because contamination is the most tangible risk, obtain a certificate of analysis showing HPLC purity (a lab test of chemical purity) above 98% and a passing endotoxin (bacterial-toxin) test, to mitigate the risk of injecting impure or contaminated material.

* **Use a low starting dose:** Beginning at the low end of reported protocols (around 100 mcg) and assessing tolerance mitigates the risk of excessive sedation, next-day grogginess, and light-headedness.

* **Dose at night and avoid driving:** Administering DSIP shortly before bed and not operating vehicles or machinery afterward mitigates the consequences of unexpected drowsiness or light-headedness.

* **Avoid combining with other sedatives:** Not stacking DSIP with alcohol, prescription or over-the-counter sleep aids, or sedating supplements mitigates the risk of additive central nervous system depression.

* **Maintain sterile injection technique:** Using sterile needles, alcohol-cleaning the injection site, and rotating sites mitigates the risk of injection-site infection and irritation.

* **Recognize the absence of long-term safety data:** Limiting duration of use and avoiding it entirely during pregnancy, breastfeeding, or with hormone-sensitive conditions mitigates exposure to unknown long-term and neuroendocrine risks.


## Therapeutic Protocol

* **Standard reported protocol:** There is no medically established protocol, since DSIP is not an approved therapy. In educational and community peptide protocols, DSIP is typically given as a subcutaneous (under-the-skin) injection of roughly 100–300 mcg, taken shortly before bedtime, in short courses rather than continuously.

* **Historical clinical dosing:** The original human studies used intravenous infusions of about 25 nmol/kg of body weight before sleep, over short courses of four to seven nights, which differs substantially from the subcutaneous self-injection now described in community protocols.

* **Competing approaches:** Approaches range from occasional single pre-sleep doses for acute poor sleep to short multi-night courses aimed at "resetting" sleep, with no consensus and no comparative trials; nasal-spray formulations are also marketed, though absorption is uncertain. No single approach is established as standard.

* **Originating experts or clinics:** The early clinical work was popularized by the Schneider-Helmert and Schoenenberger groups in Switzerland; current dosing conventions come from the peptide-experimentation community rather than any clinic or guideline body.

* **Best time of day:** Dosing is consistently described as shortly before bedtime (commonly 30–60 minutes prior), aligning with the goal of supporting night sleep.

* **Half-life considerations:** DSIP has a very short plasma half-life of roughly 15 minutes, yet reported sleep effects are said to outlast its presence in the blood, which is why dosing is timed to sleep onset rather than spread through the day.

* **Single vs. split dosing:** Protocols use a single pre-bed dose rather than split daily doses; early work found that twice-daily dosing did not improve and could blunt the night-sleep benefit.

* **Genetic polymorphisms:** No pharmacogenetic factors are known to guide DSIP dosing, given its undefined receptor and metabolism.

* **Sex-based differences:** No sex-based dosing differences have been established in the available data.

* **Age-related considerations:** No age-specific dosing guidance exists, including for older adults; the small historical studies were in middle-aged adults.

* **Baseline biomarker levels:** No baseline laboratory marker is used to guide DSIP dosing; response is judged subjectively by perceived sleep quality.

* **Pre-existing health conditions:** Any perceived benefit appears greatest in those with genuinely disturbed sleep, so the presence of an underlying sleep disturbance is the main condition-related factor in deciding whether to consider it.


## Discontinuation & Cycling

* **Lifelong vs. short-term:** DSIP is described as a short-term or intermittent aid, not a lifelong treatment; there is no evidence base supporting continuous long-term use.

* **Withdrawal effects:** No characterized withdrawal syndrome has been reported on stopping DSIP; the early studies did not describe rebound insomnia, though formal discontinuation data are lacking.

* **Tapering:** No tapering protocol is established or considered necessary, consistent with the absence of reported dependence or withdrawal.

* **Cycling:** Community protocols often suggest using DSIP in short bursts or cycles rather than nightly, on the theory of avoiding tolerance, but there is no controlled evidence that cycling preserves any effect.


## Sourcing and Quality

* **Regulatory and supply status:** DSIP is sold only as a "research chemical" or for laboratory use and is not available as an approved medicine or a regulated dietary supplement, which places all quality assurance on the buyer.

* **Purity verification:** What to look for is a current certificate of analysis confirming HPLC purity (commonly 98% or higher) and identity confirmation by mass spectrometry, so that the vial contains genuine DSIP at the stated amount.

* **Sterility and endotoxin testing:** Because the product is injected, look for documented sterility and a passing endotoxin (bacterial-toxin) test, which are minimum credibility markers for any injectable peptide.

* **Reputable suppliers:** Established peptide-chemistry suppliers such as Phoenix Pharmaceuticals and the Peptide Institute (Japan) provide research-grade DSIP with documentation; many gray-market vendors do not, and their material should be treated with caution.

* **Formulation considerations:** DSIP is usually supplied as a lyophilized (freeze-dried) powder that must be reconstituted with sterile water and kept refrigerated; degraded or improperly stored peptide loses activity, so storage and handling are part of quality.


## Practical Considerations

* **Time to effect:** Early human work reported effects on the same night and, in chronic insomniacs, a buildup over the first several nights, with sleep structure reportedly normalizing after about four doses; any benefit is therefore expected within days rather than weeks.

* **Common pitfalls:** Common mistakes include using unverified gray-market product, expecting strong sedative "knockout" effects (the peptide is reported as non-sedating), dosing too far from bedtime given its short half-life, and stacking it with alcohol or other sleep aids.

* **Regulatory status:** DSIP is not approved by the FDA for any indication. As of 2023 it was placed on the FDA's Category 2 list of bulk drug substances that may not be used in compounding, reflecting safety and evidence concerns; it is sold for research use only.

* **Cost and accessibility:** DSIP is relatively inexpensive as a research peptide but is difficult to obtain through any legitimate medical channel, and obtaining verified, high-quality material is the main accessibility hurdle.


## Interaction with Foundational Habits

* **Sleep:** Direct interaction. DSIP's entire rationale is sleep, with early studies reporting deeper, more efficient night sleep and better daytime alertness; the proposed mechanism is promotion of slow-wave sleep. Practical consideration: it is dosed shortly before bed and is best evaluated against a stable sleep schedule rather than used to paper over poor sleep habits.

* **Nutrition:** Indirect/none. No specific food interactions or nutrient depletions are documented for DSIP. Practical consideration: heavy alcohol intake near dosing should be avoided because it adds to sedation.

* **Exercise:** Indirect, potentiating. DSIP does not directly affect muscle, but better deep sleep supports physical recovery; preclinical antioxidant and recovery signals are the proposed link. Practical consideration: any recovery benefit would come through improved sleep rather than a direct training effect.

* **Stress management:** Indirect, potentiating. A large animal literature frames DSIP as "antistress," and improved sleep itself buffers stress; the proposed mechanism is neuroendocrine and antioxidant modulation. Practical consideration: it should complement, not replace, established stress-reduction practices, and human stress-hormone (cortisol) effects have not been confirmed.


## Monitoring Protocol & Defining Success

Because DSIP is an unapproved peptide with no established medical monitoring standard, the parameters below are general prudence measures rather than guideline-based requirements. Baseline testing before starting is reasonable to document general health and to have comparison values should any concern arise.

Ongoing monitoring has no validated schedule; a sensible cadence is to reassess subjective sleep and general well-being at 1 week and 4 weeks, then periodically (every 3–6 months) if use continues, recognizing that no DSIP-specific biomarker tracks its effect.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
| --- | --- | --- | --- |
| Morning cortisol | ~10–15 µg/dL | Screens stress-axis function before/after use | Draw fasting, 7–8 AM; human studies show no consistent DSIP effect, so deviations prompt other causes |
| Comprehensive metabolic panel (CMP) | Within lab reference | General organ-function safety screen | CMP is a standard blood-chemistry panel; fasting preferred; baseline plus periodic |
| Complete blood count (CBC) | Within lab reference | Baseline health and infection screen | Useful if injection-site infection is suspected |
| High-sensitivity CRP (hs-CRP) | < 1.0 mg/L | General inflammation marker | hs-CRP (C-reactive protein) is a blood marker of inflammation; can flag injection-related infection |

* **Qualitative markers:** The most meaningful "labs" for DSIP are subjective. Track:

  - Sleep quality and feeling of restedness on waking
  - Time to fall asleep and number of awakenings
  - Daytime energy, alertness, and cognitive clarity
  - Dream vividness or changes
  - Any injection-site redness, pain, or swelling

Success is best defined by consistent, reproducible improvement in these sleep and daytime measures rather than by any blood test.


## Emerging Research

* **No registered human trials:** A search of ClinicalTrials.gov returned no registered interventional trials of DSIP for sleep, longevity, or any other indication as of this review, reflecting the lack of active clinical development.

* **Preclinical stroke recovery:** Recent animal work reported that intranasal DSIP accelerated motor-function recovery after experimental stroke in rats, though it did not significantly reduce infarct size — see [Tukhovskaya et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34500605/). Future human translation would be needed to know whether any neuroprotective signal is real.

* **DSIP-like analogues and delivery:** A 2024 study engineered a DSIP fusion peptide able to cross the blood-brain barrier and reported efficacy in a chemically induced insomnia mouse model — see [Mu et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39444618/). This points to delivery and analogue design as the main direction that could revive interest.

* **Mechanistic identity question:** Research that could weaken the case continues to question whether DSIP itself is active at all; the unresolved search for a true endogenous "DSIP-like" peptide — see [Kovalzon & Strekalova, 2006](https://pubmed.ncbi.nlm.nih.gov/16539679/) — remains a fundamental open problem. If DSIP is confirmed inactive, the rationale for human use collapses.

* **Circadian and metabolic links:** Work connecting DSIP-immunoreactive material to circadian fat-tissue regulation — see [Gimble et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19849801/) — suggests a possible, unproven metabolic and longevity angle that future studies could either support or rule out.


## Conclusion

DSIP is a small natural peptide named for its early link to deep sleep, of interest to people focused on long-term health because deep sleep supports the body's nightly repair. Despite a name that promises a clear effect, the most striking feature of DSIP is how little is firmly known. A few small, mostly old human studies suggested it could improve sleep in poor sleepers without the grogginess of sleeping pills, but these results were never reliably reproduced, several came from a single research group, and the human evidence has stayed limited to small, early studies. Claims around stress resilience, antioxidant and longevity-related effects, seizures, and recovery rest almost entirely on animal studies. The evidence base is therefore thin and unsettled, and a long-standing scientific question even asks whether the peptide itself is truly active. Safety information is equally limited: short early studies found it well tolerated, but there are no long-term human data, and because it is sold only as an unapproved research chemical, the most concrete real-world concern is the quality and sterility of the product itself. It remains an experimental compound whose promise has not been matched by reliable evidence.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**